News Headlines Article

Anthem boosts coverage of XDx heart transplant test
San Francisco Business Times

Anthem Blue Cross and Blue Shield, the single largest commerical insurer in the United States, will systemically cover heart transplant patients’ use of a test from Brisbane’s XDx Inc. that determines the risk of transplant rejection. The AlloMap blood test from privately held XDx measures expression levels of 20 genes, allowing doctors to skip invasive tissue-sampling biopsies to determine if a transplanted heart is being rejected.